OBJECTIVES: We propose a new treatment strategy of Medina 0,0,1 bifurcation lesions using a dedicated side branch stent alone (Tryton Side Branch Stent™) without additional main branch stenting, with the advantage of an optimal ostial side branch coverage without the disadvantage of an excessive amount of metal in the main branch. BACKGROUND: Medina 0,0,1 lesions are relatively rare and there is no consensus on treatment strategy. Several previous techniques have been described, all with considerable disadvantages. METHODS: Between October 2009 and November 2011, 12 patients with Medina 0,0,1 lesions treated with Tryton alone were included. Clinical outcomes were reported as all-cause mortality, recurrent myocardial infarction (MI), target vessel revascularization (TVR), target lesion revascularization (TLR), and target vessel failure (TVF; defined as the composite of all-cause mortality, MI, and TVR). Procedural success was defined as successful stent placement with residual stenosis <30%, postprocedural TIMI 3 flow, and no in-hospital TVF. RESULTS: Mean age was 64 years. Median side branch reference vessel diameter was 2.6 [2.5-3.0] mm (median stenosis 75%). Procedural success was 100%. Median clinical follow-up duration was 868 [470-906] days with just one of the patients suffering from a late adverse clinical outcome: TLR at 427 days, resulting in TVF, TVR, and TLR rates of 8.3%. CONCLUSION: Treatment of Medina 0,0,1 lesions with the Tryton stent alone was associated with a 100% procedural success and only one late clinical adverse event (median follow-up of 868 days). These first positive results need to be confirmed in larger prospective randomized studies.
OBJECTIVES: We propose a new treatment strategy of Medina 0,0,1 bifurcation lesions using a dedicated side branch stent alone (Tryton Side Branch Stent™) without additional main branch stenting, with the advantage of an optimal ostial side branch coverage without the disadvantage of an excessive amount of metal in the main branch. BACKGROUND: Medina 0,0,1 lesions are relatively rare and there is no consensus on treatment strategy. Several previous techniques have been described, all with considerable disadvantages. METHODS: Between October 2009 and November 2011, 12 patients with Medina 0,0,1 lesions treated with Tryton alone were included. Clinical outcomes were reported as all-cause mortality, recurrent myocardial infarction (MI), target vessel revascularization (TVR), target lesion revascularization (TLR), and target vessel failure (TVF; defined as the composite of all-cause mortality, MI, and TVR). Procedural success was defined as successful stent placement with residual stenosis <30%, postprocedural TIMI 3 flow, and no in-hospital TVF. RESULTS: Mean age was 64 years. Median side branch reference vessel diameter was 2.6 [2.5-3.0] mm (median stenosis 75%). Procedural success was 100%. Median clinical follow-up duration was 868 [470-906] days with just one of the patients suffering from a late adverse clinical outcome: TLR at 427 days, resulting in TVF, TVR, and TLR rates of 8.3%. CONCLUSION: Treatment of Medina 0,0,1 lesions with the Tryton stent alone was associated with a 100% procedural success and only one late clinical adverse event (median follow-up of 868 days). These first positive results need to be confirmed in larger prospective randomized studies.